Press coverage about AbbVie (NYSE:ABBV) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AbbVie earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.4048716224681 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Where to Find Value in Healthcare Stocks (finance.yahoo.com)
- Kessler Investment Group, LLC Buys Apple Inc, The Home Depot Inc, Amazon. … (nasdaq.com)
- J&J (JNJ) Beats on Q3 Earnings, Actelion Buyout Drives Sales (finance.yahoo.com)
- Sanofi/Regeneron's Dupixent Succeeds in Phase II Study (finance.yahoo.com)
- Analysts Anticipate AbbVie Inc. (ABBV) Will Post Earnings of $1.38 Per Share (americanbankingnews.com)
Several research firms have recently weighed in on ABBV. BidaskClub upgraded shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, September 6th. Evercore ISI restated an “outperform” rating and set a $100.00 price objective (up from $95.00) on shares of AbbVie in a research report on Saturday, September 30th. Credit Suisse Group restated a “neutral” rating and set a $74.00 price objective (up from $65.00) on shares of AbbVie in a research report on Thursday, July 20th. Barclays PLC restated a “hold” rating and set a $68.00 price objective on shares of AbbVie in a research report on Thursday, September 28th. Finally, Cowen and Company upgraded shares of AbbVie from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $91.17 to $105.00 in a research report on Wednesday, October 11th. Seven research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $92.79.
Shares of AbbVie (ABBV) traded up 1.24% during mid-day trading on Tuesday, hitting $92.17. 5,280,458 shares of the stock traded hands. The stock has a market cap of $146.93 billion, a PE ratio of 22.67 and a beta of 1.51. AbbVie has a one year low of $55.06 and a one year high of $92.78. The stock has a 50-day moving average of $85.49 and a 200 day moving average of $72.96.
AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, July 28th. The company reported $1.42 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.02. The company had revenue of $6.94 billion during the quarter, compared to analysts’ expectations of $6.93 billion. AbbVie had a return on equity of 150.27% and a net margin of 24.77%. AbbVie’s revenue for the quarter was up 7.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.26 earnings per share. Equities analysts predict that AbbVie will post $5.53 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 15th. Investors of record on Friday, October 13th will be given a dividend of $0.64 per share. The ex-dividend date is Thursday, October 12th. This represents a $2.56 annualized dividend and a yield of 2.78%. AbbVie’s dividend payout ratio (DPR) is presently 62.90%.
In other news, insider Henry O. Gosebruch sold 18,000 shares of the stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $70.09, for a total transaction of $1,261,620.00. Following the transaction, the insider now owns 96,074 shares in the company, valued at $6,733,826.66. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Edward J. Rapp bought 4,000 shares of the stock in a transaction dated Monday, July 31st. The shares were purchased at an average price of $70.45 per share, for a total transaction of $281,800.00. Following the purchase, the director now owns 15,498 shares of the company’s stock, valued at approximately $1,091,834.10. The disclosure for this purchase can be found here. Insiders have sold 379,890 shares of company stock valued at $27,187,817 over the last three months. Insiders own 0.23% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “AbbVie (NYSE:ABBV) Earns Media Impact Score of 0.14” was published by BBNS and is the property of of BBNS. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://baseballnewssource.com/markets/abbvie-abbv-given-news-sentiment-rating-of-0-14/1700109.html.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with our FREE daily email newsletter.